KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Non-Current Deferred Tax Liability (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Non-Current Deferred Tax Liability for 17 consecutive years, with $1.1 billion as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Deferred Tax Liability rose 29.51% to $1.1 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.1 billion, a 29.51% increase, with the full-year FY2025 number at $1.1 billion, up 29.51% from a year prior.
  • Non-Current Deferred Tax Liability was $1.1 billion for Q4 2025 at Bio-Rad Laboratories, up from $872.6 million in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $3.6 billion in Q3 2021 to a low of $818.0 million in Q4 2024.
  • A 5-year average of $1.6 billion and a median of $1.5 billion in 2022 define the central range for Non-Current Deferred Tax Liability.
  • Peak YoY movement for Non-Current Deferred Tax Liability: soared 98.61% in 2021, then crashed 58.41% in 2022.
  • Bio-Rad Laboratories' Non-Current Deferred Tax Liability stood at $3.2 billion in 2021, then plummeted by 40.73% to $1.9 billion in 2022, then fell by 23.19% to $1.5 billion in 2023, then crashed by 44.56% to $818.0 million in 2024, then grew by 29.51% to $1.1 billion in 2025.
  • Per Business Quant, the three most recent readings for BIO's Non-Current Deferred Tax Liability are $1.1 billion (Q4 2025), $872.6 million (Q3 2025), and $961.0 million (Q2 2025).